- May 2013:Why Intersect ENT is an Example of Hope for the Medtech Industry
- Mar 2013:Sinus “Stent” Helps Patients Breathe Easier
- Jan 2013:Warren Man With Chronic Sinusitus Breathes Easy After Implant Surgery
- Jan 2013:Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
- May 2013:Why Intersect ENT is an Example of Hope for the Medtech Industry
- Mar 2013:Sinus “Stent” Helps Patients Breathe Easier
- Jan 2013:Warren Man With Chronic Sinusitus Breathes Easy After Implant Surgery
- Jan 2013:Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
The PROPEL® advantage

PROPEL mini, a smaller version of PROPEL, offers the same drug dose and clinical benefits. Physicians can now offer localized drug delivery to patients with less extensive surgery and smaller anatomy, allowing even more sinus sufferers to benefit from the only products in sinus surgery backed by Level 1-A evidence.
Precise, consistent, and easy placement is offered as a result of PROPEL mini's lower profile and curved delivery system.
PROPEL vs PROPEL mini DELIVERY SYSTEM
PROPEL vs PROPEL mini SIZE

ENT Surgeons can learn more about the PROPEL mini mometasone furoate implant by contacting Intersect ENT.
Click here for Instructions for Use.
Caution: Federal law (USA) restricts this product to sale by or on the order of a physician.
OPENS. DELIVERS.
MAINTAINS.
- A new treatment option for patients with less extensive surgery and smaller anatomy
- Improves surgical outcomes
SMALL BUT MIGHTY.
- Offers the same powerful drug dose (370µg) in a smaller size
- Localized drug delivery benefit over 30 days
Publications
Kennedy DW.
The PROPEL steroid releasing bioabsorbable implant to improve outcomes of sinus surgery.
Expert Review of Respiratory Medicine. 2012; 6(5):493-498.
Han JK, Marple BF, Smith TL et al.
Effect of steroid-releasing sinus implants on post-operative medical and surgical interventions.
Int Forum Allergy Rhinol. 2012; 2:271-279.


